2025-11-14T15:02:47+00:00 2024-12-31 440160260 Forvis Mazars LLP 8200 W Interstate 10 Suite 900 San Antonio TX 782303806 990 2024-01-01 462216869 Gencure GENC 2107579505 6211 IH 10 WEST SAN ANTONIO TX 78201 John Youngdahl SVP, CFO 2107579505 2025-11-14 true true Robert Ulloa P01953132 2103419400 2025-11-14 2024 2025-03-06 01:10:19Z MARTIN J LANDON 6211 IH 10 WEST SAN ANTONIO TX 78201 5427037 false X WWW.BIOBRIDGEGLOBAL.ORG X 2013 TX GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical (CONTINUED ON SCHEDULE O) 1 0 34 1 0 0 0 5018815 5411797 0 0 21383 15240 5040198 5427037 0 0 0 3816983 3938486 0 0 11216418 12101855 15033401 16040341 -9993203 -10613304 18815048 23694605 10920765 26413626 7894283 -2719021 GENCURE IS ORGANIZED TO FOCUS ON REGENERATIVE MEDICINE AND THE UTILIZATION OF THE POWER OF HUMAN CELLS AND TISSUE TO ENHANCE LIVES AND ENABLE CLINICAL ADVANCEMENTS. false false 11074605 5427037 During the reporting year, the organization advanced its enterprise-wide quality and operational infrastructure through several key initiatives. The ISO 9001:2015 certification was successfully renewed and extended to the GenCure site, reinforcing alignment across the Quality Management System and ensuring consistent standards across manufacturing, testing, and clinical operations. A full GMP compliance audit was also completed, verifying adherence to FDA regulations and confirming cGMP readiness across bioproduction and testing facilities. The organization also advanced its quality assurance framework through successful execution of process validation and system qualification activities. These efforts ensured that critical production and testing systems operate consistently within defined parameters, supporting product integrity and regulatory compliance. By validating key processes and qualifying (Continued on Schedule O) 11074605 true false false true false false false false false false true false false true true false false true false false false false false false false false false false false true false false false false false false false false false false false false false false false true true true false false true 12 0 true 34 true false false false false false false false false false false false false X 1 0 false false false false true false false true true false false false false true true true true true false false false false X Benjamin Lopez 2107579505 6211 IH 10 West San Antonio TX 78201 BIOBRIDGE GLOBAL SOLE MEMBER 1.0 3.0 X 0 0 0 GEOFFREY KINDT General Manager, Biomanufacturing (thru 11/02/2024) 50.0 50.0 X 260606 28837 84913 AMANDA WHITELONIS Principal Global Market Development (effective 11/03/2024) 50.0 50.0 X 20119 171875 27276 MARI LANE SALMI SR. DIRECTOR, PROCESS DEV & CELL THERAPIES 50.0 0 X 203361 0 40993 Miguel Garza Director, Operations Biomanufacturing 50.0 0 X 156301 0 19855 MILTON MASAYUKI POLLARD VP, GENCURE OPERATIONS (thru 07/09/2024) 50.0 0.0 X 196274 0 23473 ROGELIO ZAMILPA Executive Director, Biomanufacturing & Collab 50.0 0 X 215099 0 27522 1051760 200712 224032 12 false true false CAM PHARMACEUTICAL CONSULTING LLC 1100 WOODBROOK WAY GARNER NC 27529 BIOTECH CONSULTING SERVICES 0 0 BIOMANUFACTURING SERVICE FEES 621991 5411797 5411797 0 0 0 0 5411797 0 0 0 0 PURCHASE REBATES 621300 15240 15240 0 0 0 0 15240 5427037 5427037 0 0 314979 314979 2933036 2933036 147204 147204 341515 341515 201752 201752 70419 70419 0 0 181 181 269845 269845 24151 24151 1406336 1406336 45196 45196 22667 22667 96392 96392 1674203 1674203 7651 7651 SUPPORT & ADMINISTRATIVE FEE 5684309 726224 4958085 TESTING EXPENSES & SUPPLIES 1545823 1545823 EQUIPMENT MAINTENANCE 487396 487396 BAD DEBT EXPENSE 481944 481944 285342 285342 0 0 16040341 11074605 4965736 0 154464 216927 991756 1148507 0 0 0 0 1279936 1535957 113427 222219 18804590 7496280 11018762 11308310 0 0 5256703 9262685 18815048 23694605 593174 1731869 0 0 4159848 2429212 6167743 22252545 10920765 26413626 X 7894283 -2719021 7894283 -2719021 18815048 23694605 -10613304 0 X false true true false X 245835 0 0 0 0 245835 11388400 3990807 5012409 5040198 5427037 30858851 0 0 0 11634235 3990807 5012409 5040198 5427037 31104686 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 31104686 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 11634235 3990807 5012409 5040198 5427037 31104686 1 0.99494 0 0.01 X 11074605 11074605 703730 0 175933 0 0 681936 836051 652068 703730 2873786 4310678 0 0 0 0 0 170484 209013 163017 175933 718446 1077670 0 0 0 0 0 612187 288942 323245 5556761 1384605 4172156 12093910 5727886 6366024 541732 94847 446885 11308310 INTERCOMPANY RECEIVABLE RIGHT-OF-USE ASSETS - LEASES 9262685 9262685 Federal Income Taxes OPERATING LEASE LIABILITIES 10140042 INTERCOMPANY PAYABLES 12112503 22252545 5427037 0 0 5427037 0 0 5427037 16040341 0 0 16040341 0 0 16040341 Schedule D, Part X, Line 2 ASC 740 FOOTNOTE MANAGEMENT HAS EVALUATED THEIR INCOME TAX POSITIONS UNDER THE GUIDANCE INCLUDED IN ASC 740. BASED ON THEIR REVIEW, MANAGEMENT HAS NOT IDENTIFIED ANY MATERIAL UNCERTAIN TAX POSITIONS TO BE RECORDED OR DISCLOSED IN THE FINANCIAL STATEMENTS. false false false false false true true false false GEOFFREY KINDT General Manager, Biomanufacturing (thru 11/02/2024) 215573 28364 42706 0 2327 473 16023 1730 34441 32719 311070 63286 0 0 AMANDA WHITELONIS Principal Global Market Development (effective 11/03/2024) 19763 145730 0 25130 356 1015 1211 10364 7774 7927 29104 190166 0 0 MILTON MASAYUKI POLLARD VP, GENCURE OPERATIONS (thru 07/09/2024) 131895 0 25000 0 39379 0 10397 0 13076 0 219747 0 0 0 ROGELIO ZAMILPA Executive Director, Biomanufacturing & Collab 186736 0 25000 0 3363 0 10882 0 16640 0 242621 0 0 0 MARI LANE SALMI SR. DIRECTOR, PROCESS DEV & CELL THERAPIES 176189 0 25000 0 2172 0 5321 0 35672 0 244354 0 0 0 Miguel Garza Director, Operations Biomanufacturing 155244 0 0 0 1057 0 4594 0 15261 0 176156 0 0 0 Schedule J, Part I, Line 3 Arrangement used to establish the top management official's compensation THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS THAT USED ONE OR MORE OF THE METHODS LISTED IN SCHEDULE J, PART I, LINE 3 TO ESTABLISH THE TOP MANAGEMENT OFFICIAL'S COMPENSATION. Schedule J, Part I, Line 6a Compensation contingent on net earnings of the organization THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS OF DETERMINING THE COMPENSATION CONTINGENT ON THE ORGANIZATION'S EARNINGS. THE PROCESS IS DISCLOSED ON THEIR FORM 990. Schedule J, Part I, Line 6b Compensation contingent on net earnings of a related organization THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS OF DETERMINING THE COMPENSATION CONTINGENT ON THE ORGANIZATION'S EARNINGS. THE PROCESS IS DISCLOSED ON THEIR FORM 990. Form 990, Part I, Line 1 Brief Mission GenCure enables progress in the field of advanced therapies (also known as cell & gene therapies) by offering process and analytical development, bioproduction; in-process and release testing, while leveraging a unified quality management system. We partner with our users with the end goal of clinical development in mind, supporting development of therapies often originating from academic research institutions. Form 990, Part III, Line 4a DESCRIPTION OF ORGANIZATION'S MISSION OR MOST SIGNIFICANT ACTIVITIES During the reporting year, the organization advanced its enterprise-wide quality and operational infrastructure through several key initiatives. The ISO 9001:2015 certification was successfully renewed and extended to the GenCure site, reinforcing alignment across the Quality Management System and ensuring consistent standards across manufacturing, testing, and clinical operations. A full GMP compliance audit was also completed, verifying adherence to FDA regulations and confirming cGMP readiness across bioproduction and testing facilities. The organization also advanced its quality assurance framework through successful execution of process validation and system qualification activities. These efforts ensured that critical production and testing systems operate consistently within defined parameters, supporting product integrity and regulatory compliance. By validating key processes and qualifying essential systems, the organization reinforced its readiness for scale-up and sustained operational excellence. Operational performance improved significantly, with cleanroom utilization averaging 27 days per month-a fourfold increase over Q4 2023 figures. This achievement met the corporate target of a 20% year-over-year production increase, reflecting enhanced throughput and resource optimization. To support additional growth, the organization prepared its site for activation of new liquid nitrogen cryogenic storage, expanding cryopreservation capacity. Additionally, a relocation into additional administrative and warehouse suites consolidated logistics and production support functions, streamlining operations and improving infrastructure integration. These accomplishments demonstrate the organization's commitment to quality, compliance, and scalable growth in support of its mission. Form 990, Part VI, Line 8a DOCUMENTATION OF MEETINGS OR WRITTEN ACTIONS BY THE GOVERNING BODY MEETINGS HELD AND WRITTEN ACTIONS UNDERTAKEN WERE DOCUMENTED IN THE MINUTES OF THE MEETINGS OF BIOBRIDGE GLOBAL'S BOARD OF DIRECTORS. Form 990, Part VI, Line 15a REVIEW OF CEO/TOP MANAGEMENT COMPENSATION IN DETERMINING THE TOP MANAGEMENT OFFICIAL'S COMPENSATION, THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS TO ASSIST IN COMPENSATION DECISIONS. THE PROCESS OF DETERMINING THE TOP MANAGEMENT COMPENSATION IS DISCLOSED ON THEIR FORM 990. Form 990, Part VI, Line 15b REVIEW OF OTHER OFFICER'S COMPENSATION THE ORGANIZATION RELIED ON BIOBRIDGE GLOBAL'S PROCESS TO ASSIST IN COMPENSATION DECISIONS. THE PROCESS OF DETERMINING OTHER OFFICER'S COMPENSATION IS DISCLOSED ON THEIR FORM 990. Form 990, Part VI, Line 6 Classes of members or stockholders BIOBRIDGE GLOBAL IS THE SOLE MEMBER OF THE CORPORATION. Form 990, Part VI, Line 11b Review of form 990 by governing body THE ORGANIZATION ENGAGES AN OUTSIDE ACCOUNTING FIRM TO PREPARE THE FORM 990. ONCE PREPARED, THE RETURN IS REVIEWED BY THE FINANCIAL MANAGEMENT STAFF FROM BIOBRIDGE GLOBAL, A RELATED ORGANIZATION. A COPY OF THE FORM 990 IS PROVIDED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF DIRECTORS OF BIOBRIDGE GLOBAL PRIOR TO FILING. Form 990, Part VI, Line 12c Conflict of interest policy A COPY OF THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED ANNUALLY TO ALL OFFICERS, KEY EMPLOYEES, AND BOARD OF DIRECTORS OF BIOBRIDGE GLOBAL. IN ADDITION, QUESTIONNAIRES ARE GIVEN OUT ON AN ANNUAL BASIS TO ALL OFFICERS, KEY EMPLOYEES AND BOARD OF DIRECTORS WHICH COVER BUSINESS AND FAMILY RELATIONSHIPS AND VARIOUS ACTIVITIES THAT HAVE OCCURRED OVER THE COURSE OF THE YEAR. EVERY ATTEMPT IS MADE TO ENSURE THAT ALL FORMS ARE RETURNED. INDIVIDUALS WHO FAIL TO RETURN THE REQUESTED FORMS OR PROVIDE INCOMPLETE INFORMATION ARE CONTACTED BY THE ORGANIZATION. IN THE EVENT OF A CONFLICT OF INTEREST, THE MEMBER SUBJECT TO THE CONFLICT OF INTEREST MUST LEAVE THE DISCUSSION AND VOTING ON A TRANSACTION OR ARRANGEMENT THAT RESULTS IN A CONFLICT OF INTEREST. A COMMITTEE OF NON-INTERESTED REPRESENTATIVES SHALL BE APPOINTED TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. THE PARTY WITH A CONFLICT OF INTEREST IS NOT PERMITTED TO ADVOCATE TO OTHER REPRESENTATIVES PRIOR TO THE VOTE. THE COMMITTEE IS RESPONSIBLE FOR EXERCISING DUE DILIGENCE IN DETERMINING THAT THE TRANSACTION IS NOT MORE MATERIALLY ADVANTAGEOUS THAN A DEAL WITH A NON-INTERESTED TRANSACTION. Form 990, Part VI, Line 19 Required documents available to the public ANY DOCUMENTS SUBJECT TO OPEN RECORD REQUIREMENTS ARE MADE AVAILABLE UPON REQUEST. SOUTH TEXAS BLOOD & TISSUE CENTER 6211 IH 10 WEST SAN ANTONIO TX 78201 237379332 BLOOD BANK TX 501(c)(3) 10 BIOBRIDGE GLOBAL true THE BLOOD & TISSUE CENTER FOUNDATION 6211 IH 10 WEST SAN ANTONIO TX 78201 431970952 SUPPORT ORG. TX 501(c)(3) Type I BIOBRIDGE GLOBAL true BIOBRIDGE GLOBAL 6211 IH 10 WEST SAN ANTONIO TX 78201 454765222 SUPPORT ORG. TX 501(c)(3) Type II NA false QUALTEX LABORATORIES 6211 IH 10 WEST SAN ANTONIO TX 78201 208429619 TEST PUBLIC SAFETY AZ 501(c)(3) 11 BIOBRIDGE GLOBAL true HELPING HEARTS FUND 6211 IH10 WEST SAN ANTONIO TX 78201 871628709 Employee Assistance TX 501(c)(3) 7 BIOBRIDGE GLOBAL true false false false false true false false false false false false false true true true true true true true QUALTEX LABORATORIES M 370526 BOOK COST